Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab

PURPOSE: Inotuzumab ozogamicin (INO) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. We performed a phase I/II study to determine the maximum-tolerated dose (MTD), safety, efficacy, and pharmacokinetics of I...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Fayad, Luis, Offner, Fritz, Smith, Mitchell R., Verhoef, Gregor, Johnson, Peter, Kaufman, Jonathan L., Rohatiner, Ama, Advani, Anjali, Foran, James, Hess, Georg, Coiffier, Bertrand, Czuczman, Myron, Giné, Eva, Durrant, Simon, Kneissl, Michelle, Luu, Kenneth T., Hua, Steven Y., Boni, Joseph, Vandendries, Erik, Dang, Nam H.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2013
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878046/
https://ncbi.nlm.nih.gov/pubmed/23295790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.42.7211
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados